|
Disease
|
Patients group and p value
|
RI
|
NRM
|
LFS
|
OS
|
cGVHD
|
|---|
|
Diagnosis
|
AML
|
36.1 % (31.6–40.6)
|
31.6 % (27.4–35.9)
|
32.2 % (27.7–36.7)
|
37.7 % (33.1–42.4)
|
29.2 % (24.8–33.7)
|
| |
ALL
|
40 % (32.5–47.3)
|
32.9 % (28.6–37.2)
|
27.2 % (20.2–34.1)
|
33.3 % (25.9–40.7)
|
29.8 % (22.8–37.2)
|
| |
p
|
0.43
|
0.87
|
0.45
|
0.40
|
0.67
|
|
All patients
| | | | | | |
|
CR1
|
RIC
|
30.1 % (19.1–41.9)
|
31.1 % (24.1–38.3)
|
38.9 % (26.4–51.3)
|
46.9 % (34.1–59.8)
|
26 % (15–38.3)
|
| |
MAC
|
21.5 % (15.4–28.3)
|
29.1 % (22.2–36.3)
|
49.1 % (41.2–57.1)
|
55.4 % (47.5–63.4)
|
41 % (32.8–48.9)
|
| |
p
|
0.21
|
0.80
|
0.42
|
0.64
|
0.10
|
|
≥ CR2
|
RIC
|
38.5 % (25.8–51.1)
|
36.8 % (28.2–45.5)
|
24.6 % (13.1–36.1)
|
29.8 % (17.7–41.9)
|
29.6 % (17.5–42.8)
|
| |
MAC
|
30 % (21.5–39)
|
27.8 % (19.7–36.4)
|
42.2 % (32.6–51.7)
|
47.7 % (38–57.5)
|
37 % (27.4–46.6)
|
| |
p
|
0.38
|
0.25
|
0.06
|
0.07
|
0.53
|
|
Active dis.
|
RIC
|
55.8 % (45.9–64.6)
|
32.9 % (24.5–41.5)
|
11.3 % (5–17.5)
|
14.3 % (7.3–21.3)
|
21.4 % (13.8–30.1)
|
| |
MAC
|
51.9 % (42.3–60.6)
|
37.1 % (28.6–45.7)
|
11 % (4.7–17.2)
|
18.5 % (11.2–25.7)
|
15.2 % (9.2–22.7)
|
| |
P
|
0.52
|
0.38
|
0.64
|
0.60
|
0.29
|
-
Active dis active disease, cGVHD chronic graft-versus-host disease, CR complete remission, LFS leukemia-free survival, NRM non-relapse mortality, MAC myeloablative conditioning, OS overall survival, RI relapse incidence, RIC reduced intensity conditioning
